NEW YORK (GenomeWeb News) –GenapSys said today that it has raised $37 million in a Series B financing round to support commercialization of its next-generation sequencing platform.

The Series B financing includes new investors Yuri Milner, Stanford StartX Fund, and other private and institutional investors.

The Redwood City, Calif.-based company is developing a next-gen sequencing system called GENIUS 110, which stands for Gene Electronic Nano-Integrated Ultra-Sensitive.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Alnylam's RNAi-based therapy Onpattro, according to Stat News.

Harvard Medical School's Seth Cassel and Cigall Kadoch argue in a Baltimore Sun op-ed that the recent TAILORx trial shows the potential of genomic-based medicine.

Researchers in the UK are working on using gene drives to control malaria-carrying mosquitoes, the Telegraph reports.

In PLOS this week: genetic architecture mediating gene expression, metabolomic patterns in multiple myeloma, and more.

Sep
17
Sponsored by
SeraCare

Today’s challenging clinical next-generation sequencing applications require a rigorous, comprehensive quality control management program to ensure confidence in results.